SEC EDGARAUG 281 min read$TEM

LEFKOFSKY ERIC P sold $828K of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 11,848 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $69.87 ($69.83–$70.58, $0.83M total) across 2 trades on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · LEFKOFSKY ERIC P

Published Aug 28, 2026, 12:28 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 28, 2026, 12:34 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TEM

Bearish

medium confidence

Mentioned

$TEM

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TEMBearishLow

Why it matters

The disclosed sale provides fresh data on insider sentiment, useful for short‑term traders.

Market read

Primary insider sale news; modest materiality but relevant for short‑term price action.

What to watch

The CEO retains a sizable stake (150,000 shares) and the sale was pre‑planned, which may mitigate concerns.

Relevance 4/10Novelty 6/10Timing: filing disclosed today

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan allows pre‑arranged sales.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TEMBearishMedium confidence

Context

CEO Eric Lefkofsky sold 11,848 shares for $828K via a 10b5-1 plan, reducing his stake to 150,000 shares.

Expected impact

Potential modest downside pressure over the next few days.

Evidence & confidence

A $828K sale by the CEO is material for a mid‑cap biotech, but the amount is modest relative to market cap.

Market effects

Sector

May raise questions about Tempus AI's near‑term outlook among biotech investors.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Minimal global impact beyond the company's share price.

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged plan and not reflect negative sentiment.

Key entities

Company
Tempus AI, Inc.
Biotech firm focused on AI‑driven clinical data platforms.
Executive
Eric Lefkofsky
CEO and Chairman of Tempus AI.

Read at source ← All news

SEP 17

$TEMMedAI 8/10

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

Tempus AI Inc. (NASDAQ: TEM) shares rose 14.38% on September 17, 2026, driven by strong Q2 2026 results. Revenue grew 22% YoY to $382.5M, with net income and EBITDA turning positive at $5.6M and $45M, respectively. Gross margin is 73.5%. The company plans to acquire Personalis, funded by $816M in cash and investments, despite $1.36B in long-term debt. TEM's stock has surged from $62 to $80, attracting momentum traders.

timothysykes.com3 min

SEP 17

$TEMMed

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI (TEM) shares surged 29.98% this week after Morgan Stanley highlighted new reimbursement-driven revenue growth. CEO Eric Lefkofsky estimated xT pricing could add $80M-$100M in 2025, and xF approval $250M-$300M annually. Q2 revenue was $382.49M, up 21.6% YoY, with full-year guidance raised to $1.595B-$1.605B. Analysts revised FY2027 EPS estimates positively, with a consensus revenue estimate of $1.97B.

247wallst.com2 min

SEP 15

$TEMHighAI 8/10

Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. (TEM) shares rose 6.62% after Piper Sandler upgraded it to Overweight with a $76 price target. The company reported Q2 2026 revenue of $382.5M, up 22% YoY, and turned profitable. TEM is acquiring Personalis for $1.5B to expand its tumor-sequencing platform. The stock trades near $66.33, with strong cash position and improving margins.

stockstotrade.com3 min

SEP 5

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

finance.biggo.com4 min

SEP 2

$TEMHighAI 9/10

Tempus AI gets FDA clearance for pulmonary hypertension AI tool

Tempus AI (NASDAQ: TEM) received FDA clearance for its AI tool, Tempus ECG-PH, which analyzes ECGs for pulmonary hypertension. This is the third FDA-cleared device in its cardiovascular portfolio. Tempus shares rose 5.09% to $70.04, driven by positive Phase 3 trial results from Moderna and Merck, which validate the $1.5 billion acquisition of Personalis.

scanx.trade3 min